In a randomized controlled trial, empagliflozin was demonstrated to reduce liver fat and improve alanine transaminase levels in patients with T2D and NAFLD, but this effect did not correlate with glycemic improvement or body weight reduction (78). The gene discussed is GPT; the disease is type 2 diabetes mellitus.